anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Disclosed is a composition which can accelerate the production of adiponectin, is not problematic in terms of safety issues such as side effects or toxicity, and can be orally administered. The adiponectin production accelerating composition has the effect of accelerating adiponectin production, contains salmon milt extract, brewer's yeast extract, avian collagen and mineral containing yeast. It is preferable that the salmon milt extract contains low-molecular components broken up as far as olignucleotides and oligopeptides by enzyme treating salmon milt. It is preferable that the brewer's yeast extract contains 50-80% RNA. It is preferable that the mineral containing yeast contains 0.01-0.02% selenium, 0.3-0.5% copper and 2-3% zinc in dry yeast. Furthermore, it is preferable that 16-17 parts by mass of the brewer's yeast extract, 33-34 parts by mass of the avian collagen, and 22-23 parts by mass of the mineral containing yeast are included per 100 parts by mass of the salmon milt extract.
The increased availability of large clinical datasets together with increasingly sophisticated computing power has facilitated development of numerous risk prediction models for various adverse perioperative outcomes, including acute kidney injury (AKI). The rationale for developing such models is straightforward. However, despite numerous purported benefits, the uptake of preoperative prediction models into clinical practice has been limited. Barriers to implementation of predictive models, including limitations in their discrimination and accuracy, as well as their ability to meaningfully impact clinical practice and patient outcomes, are increasingly recognised. Some of the purported benefits of predictive modelling, particularly when applied to postoperative AKI, might not fare well under detailed scrutiny. Future research should address existing limitations and seek to demonstrate both benefit to patients and value to healthcare systems from implementation of these models in clinical practice.
Patients with stage II seminoma will be offered Carboplatin AUC10. Those deemed ineligible for Carboplatin AUC10 or who decline this treatment option will be offered either BEP/EP chemotherapy or radiotherapy and will continue to be followed in the study.
The invention relates to loratadine lyophilized tablets, and a lyophilization prescription and a technology thereof. The loratadine lyophilized tablets provided by the invention are prepared from a main medicine loratadine and medicinal auxiliary materials. When the tablets are taken, no water is used, and the tablets disintegrate rapidly in mouths. Therefore, the tablets are suitable for patients with swallowing difficulties such as old people and children. Also, the tablets are suitable to be used in trips with water source shortages. The tablets are advantaged in convenient administration, fast absorption, small first-pass effect, and small irritation to gastrointestinal mucous membranes. The market prospect of the tablets is wide. With the lyophilized tablets provided by the invention, side effects of loratadine can be substantially reduced. Also, the invention relates to a preparation method of the loratadine lyophilized tablets.
PURPOSE: To obtain a Gloiopeltis preparation suitable for package, capable of being extremely easily used, and exhibiting a beautifying effect as a bathing agent or a treatment agent by coarsely grinding Gloiopeltis containing various medicinal ingredients into a specific granular size. CONSTITUTION: The Gloiopeltis preparation is obtained by coarsely grinding a primitive alga, Gloiopeltis, into granules of 10-100 meshes. Especially, a bathing agent is obtained by grinding the Gloiopeltis into the granules of 10-60 meshes and subsequently sealing the granules in a water-permeable packaging bag. A treatment agent is also obtained by grinding the Gloiopeltis into the granules of 20-100 meshes. The coarsely ground Gloiopeltis may be compounded with Coix seed in a ratio of approximately 3:1. The Gloiopeltis preparation containing the Coix seed exhibits effects such as an effect enabling to remove the old corneum and stains of skin and aid the absorption of the Gloiopeltis ingredients.  When the Gloiopeltis is used as the bathing agent or the treatment agent, a skin-softening action, a heat-insulating action, a blood circulation-stimulating action, a cell-activating action, and beautifying effects such as a lean body action and a body-tightening action can be expected.
OBJECTIVE: Examine pressure injury (PrI) pain severity, stability, and current treatment of PrI pain among nursing home (NH) residents using two assessment tools and a descriptive cohort study design.
BACKGROUND: PrI pain affects quality of life of NH residents yet, best assessment methods, stability of PrI pain, and how to take care of the pain are not well known.
METHODS: Data collected from 33 residents with PrI (stages 1-4) from 4 NHs. All PrI were staged and assessed using the Bates-Jensen Wound Assessment Tool (BWAT) to determine severity. Verbal Response Scale (VRS) and Pain Assessment in Advanced Dementia (PAINAD) were used to assess general and PrI pain 3 times a day for two days within one week. Data classified as: no, mild, moderate, or severe pain. Proportions of participants with different levels of PrI pain were calculated. T tests were conducted to examine differences across time; VRS and PAINAD were examined for agreement.
RESULTS: Participants were 74 % female, 49 % white, 58 % cognitively intact, 58 % functionally dependent, and had mean age of 82 years old. The majority (52 %; n = 17) were full thickness PrI, stage 3 (n = 5), stage 4 (n = 7), unstageable (n = 5). The majority of participants (82 %; n = 27) reported PrI pain on at least one of six assessments over the two days; with 57 % mild, 26 % moderate and 16 % severe pain. More severe pain occurred in afternoon. No differences existed across days. Although there was a positive relationship between VRS and PAINAD in pain assessments (r = 0.38, P<.05), the agreement between the two scales, as indicated by Cohen's kappa (K = 0.19, p=.28), was found to be poor. Of those with PrI pain, 22 % had pain documented in the Minimum Data Set (MDS). Only 42 % of participants who reported PrI pain received pain medication within 12 h of initial pain assessment. Out of 28 participants who received routine pain medication for general pain, 18 of them reported experiencing no pain.
CONCLUSION: While VRS and PAINAD scores exhibited a relationship, their agreement was limited. Documentation of PrI pain on the Minimum Data Set (MDS) was found to be inadequate. Notably, 40 % of participants reported higher levels of PrI pain in the afternoon, suggesting this time may be opportune for PrI pain assessment and management. Interestingly, participants who received medication for general pain did not report PrI pain, suggesting that treatment of general pain may effectively alleviate PrI pain symptoms.
PURPOSE: To continuously, rapidly and easily form mineralized water by impregnating hot water of a specific temp. or above with granite porphyry and in addition, to apply the granite porphyry, which is non-drugs, to various kinds of applications and to expand the utilization range thereof by effectively utilizing the granite porphyry. CONSTITUTION: The hot water of >=70 deg.C is impregnated with the granite porphyry, by which the mineralized water is continuously, rapidly and easily foamed at the time of forming the mineralized water by utilizing the granite porphyry. On the other hand, tea bags of the granite porphyry are formed by molding the granite porphyry to a granular form and sealing such granite porphyry into bags. Food, such as fish, meat, vegetables and fruits, are pickled into the powder of the granite porphyry and are thereby made preservable over a long period. Further, the granite porphyry chloride is formed by mixing the fine powder of the granite porphyry and common salt. This granite porphyry chloride is dissolved in water and is drunk for stopping pain.  The granite porphyry is applied to various kinds of the applications and its utilization range is expanded by effectively utilizing the granite porphyry which is non-drugs, in such a manner.
A food composition containing arabinose-coated low calorie sugar or arabinose-containing frost sugar is provided to secure a constant ratio of arabinose and sugar in every part of food due to the arabinose coated with low calorie sugar. A particle-like or powder-like food composition comprises arabinose-coated sugar or arabinose-containing frost sugar. The arabinose-coated sugar is obtained by coating refined sugar or brown sugar with an arabinose solution. The arabinose solution is prepared by dissolving powder-like arabinose in a solvent such as water. The 1-3 parts of solvent is added to the 1 part of arabinose by weight. The arabinose-containing frost sugar is prepared by mixing powder-like arabinose to pulverized sugar and adding a solvent to obtain mixed material. The arabinose-containing frost sugar has a 10~40 mesh of particle size.
Cerebral microhemorrhages (CMHs, also known as cerebral microbleeds) are a critical but frequently underestimated aspect of cerebral small vessel disease (CSVD), bearing substantial clinical consequences. Detectable through sensitive neuroimaging techniques, CMHs reveal an extensive pathological landscape. They are prevalent in the aging population, with multiple CMHs often being observed in a given individual. CMHs are closely associated with accelerated cognitive decline and are increasingly recognized as key contributors to the pathogenesis of vascular cognitive impairment and dementia (VCID) and Alzheimer's disease (AD). This review paper delves into the hypothesis that atherosclerosis, a prevalent age-related large vessel disease, extends its pathological influence into the cerebral microcirculation, thereby contributing to the development and progression of CSVD, with a specific focus on CMHs. We explore the concept of vascular aging as a continuum, bridging macrovascular pathologies like atherosclerosis with microvascular abnormalities characteristic of CSVD. We posit that the same risk factors precipitating accelerated aging in large vessels (i.e., atherogenesis), primarily through oxidative stress and inflammatory pathways, similarly instigate accelerated microvascular aging. Accelerated microvascular aging leads to increased microvascular fragility, which in turn predisposes to the formation of CMHs. The presence of hypertension and amyloid pathology further intensifies this process. We comprehensively overview the current body of evidence supporting this interconnected vascular hypothesis. Our review includes an examination of epidemiological data, which provides insights into the prevalence and impact of CMHs in the context of atherosclerosis and CSVD. Furthermore, we explore the shared mechanisms between large vessel aging, atherogenesis, microvascular aging, and CSVD, particularly focusing on how these intertwined processes contribute to the genesis of CMHs. By highlighting the role of vascular aging in the pathophysiology of CMHs, this review seeks to enhance the understanding of CSVD and its links to systemic vascular disorders. Our aim is to provide insights that could inform future therapeutic approaches and research directions in the realm of neurovascular health.
When Fluorouracil Cream USP is applied to a lesion, a response occurs with the following sequence: erythema, usually followed by vesiculation, desquamation, erosion, and re-epithelialization.

Fluorouracil Cream USP should be applied preferably with a nonmetal applicator or suitable glove. If Fluorouracil Cream USP is applied with the fingers, the hands should be washed immediately afterward.

Actinic or Solar Keratosis:   
Apply cream twice daily in an amount sufficient to cover the lesions. Medication should be continued until the inflammatory response reaches the erosion stage, at which time use of the drug should be terminated. The usual duration of therapy is from 2 to 4 weeks. Complete healing of the lesions may not be evident for 1 to 2 months following cessation of Fluorouracil Cream USP therapy.
Participants will be onboarded to Flourish by a research study clinician, following which they will receive a text messaging program for 4 weeks as well as an accompanying resources website. As part of the text messaging program, participants will receive brief questionnaires evaluating their online experiences once every 3 days.
PURPOSE: An antiviral composition against calicivirus, containing a Rubus coreanus extract as an active ingredient is provided to effectively suppress proliferation and replication of calicivirus, thereby being used as an effective therapeutic agent for treating norovirus and feline calicivirus. CONSTITUTION: An antiviral composition against calicivirus contains a Rubus coreanus extract as an active ingredient. The extract is prepared by juicing, steam extraction, hot water extraction, sonication, solvent extraction, or reflux condensation. The extract is prepared by solvent extraction using a solvent selected among water, ethanol, an ethanol solution, and an acetic acid solution. The extract has an antiviral activity by suppressing proliferation and replication of calicivirus. The calicivirus is norovirus or feline calicivirus. [Reference numerals] (AA) Survival rate of RAW 264.7 cell (%); (BB,DD) Concentration of rubus coreanus extract (%); (CC) Survival rate of CRFK cell (%)
Methods and systems for monitoring health status of chronically ill people are provided. An example system includes a wearable device with sensors, with the wearable device being designed to be worn on a wrist of a patient. The wearable device is operable to continuously collect, via sensors, sensor data from a single place on body of the patient. The sensor data are processed to obtain electrocardiogram data and photoplethysmogram data. The electrocardiogram data and the photoplethysmogram data are analyzed to obtain medical parameters associated with a chronic disease. Based at least partially on the changes in the medical parameters over time, a progression of the at least one chronic disease can be determined. Based on the progression, messages regarding the current health condition are sent to the patient. The messages include advice to take medicine or contact a medical professional if a chronic condition is worsening.
Inventors:  MILTON B. DOBKIN     Invention:  HIGH TITER ANTI-RESPIRATORY SYNCYTIAL               VIRUS INTRAVENOUS IMMUNE GLOBULIN     Abstract of the Disclosure Normal plasma from donors who have not necessarily been vaccinated with a respiratory syncytial virus vaccine can be screened for higher than normal titers of naturally occurring antibody to respiratory syncytial virus (e.g. minimum ELISA titer of at least 1:110,000).  Those plasmas with high titers of such antibody can be pooled and fractionated to give hyperimmune globulin.  The product may be treated to render it suitable for intravenous injection. Patients with respiratory syncytial virus infection or at risk of such infection, may receive the present product to raise serum antibody titers to respiratory syncytial virus. Resultant product has an ELISA anti-RSV titer of at least about 1:250,000.
Dose escalation in up to 6 dose cohorts. Subjects will be administered a single dose of NI006 in the SAD, multiple doses of NI006 in the MAD and OLE phases.
<P>PROBLEM TO BE SOLVED: To disclose highly hydrophilic indole and benzoindole derivatives that absorb light in the visible region of light and generate fluorescence.  <P>SOLUTION: The novel composition of this invention contains a dye which is hydrophilic, absorbs light of electromagnetic spectrum in the visible and near infrared region, and is represented by anyone of formula 1 to formula 6. The clearance pathway of the dye after in vivo administration is easy, enabling the use of the composition for physiological monitoring. Therefore, a blood protein binding compound is useful for angiography and organ perfusion analysis, especially useful for organ transplant and a fatal sick patient. Renal clearance of the dye is dominant, enabling the dye to be used for dynamic renal function monitoring; and quick liver uptake of the dye from blood is helpful as an index useful for liver function evaluation. These compounds are useful for physiological and organic functional monitoring.  <P>COPYRIGHT: (C)2009,JPO&INPIT
BACKGROUND: The University of California's Diabetes Prevention Program (UC DPP) Initiative was implemented systemwide to address diabetes and obesity risk on all 10 campuses. As little is known about implementing lifestyle change programs in university settings, we examined implementation partners' (i.e., UC DPP leaders and campus leads) perceptions of factors influencing program success on UC campuses.
METHODS: We conducted qualitative interviews with UC DPP leaders and campus leads to examine challenges and opportunities with university-based DPP delivery models. Interviews were recorded, professionally transcribed, and reviewed in detail by the research team. Transcripts were analyzed using rapid qualitative analysis (RQA). The study was approved by the UCLA Institutional Review Board. All implementation partners provided verbal informed consent.
RESULTS: Twenty-six implementation partners (8 UC DPP leaders and 18 campus leads) completed interviews in 2021. Seven themes were identified as critical for implementation, including (1) marketing and recruitment (i.e., market and recruit broadly through established channels as well as target at-risk populations); (2) enrollment (i.e., offer the program during convenient times and let participants know what to expect); (3) use an adaptable, evidence-based program; (4) secure funding for the program, participants, lifestyle coaches, and space; (5) hire experienced and dedicated staff and lifestyle coaches; (6) ensure leadership support; and (7) utilize campus linkages and resources. Perceptions of challenges faced with respect to these themes are also described.
CONCLUSIONS: This is one of the first studies to examine the challenges and opportunities of delivering an intensive lifestyle change program across 10 university sites. Understanding factors that enhance success of university-based diabetes prevention programs can facilitate UC DPP efforts and help inform delivery strategies of health and wellness programs across other university settings more broadly.
BACKGROUND: Alcohol-related liver disease (ALD) is a major health concern worldwide, but effective therapeutics for ALD are still lacking. Tumor necrosis factor-inducible gene 6 protein (TSG-6), a cytokine released from mesenchymal stem cells, was shown to reduce liver fibrosis and promote successful liver repair in mice with chronically damaged livers. However, the effect of TSG-6 and the mechanism underlying its activity in ALD remain poorly understood.
METHODS: To investigate its function in ALD mice with fibrosis, male mice chronically fed an ethanol (EtOH)-containing diet for 9 weeks were treated with TSG-6 (EtOH + TSG-6) or PBS (EtOH + Veh) for an additional 3 weeks.
RESULTS: Severe hepatic injury in EtOH-treated mice was markedly decreased in TSG-6-treated mice fed EtOH. The EtOH + TSG-6 group had less fibrosis than the EtOH + Veh group. Activation of cluster of differentiation 44 (CD44) was reported to promote HSC activation. CD44 and nuclear CD44 intracellular domain (ICD), a CD44 activator which were upregulated in activated HSCs and ALD mice were significantly downregulated in TSG-6-exposed mice fed EtOH. TSG-6 interacted directly with the catalytic site of MMP14, a proteolytic enzyme that cleaves CD44, inhibited CD44 cleavage to CD44ICD, and reduced HSC activation and liver fibrosis in ALD mice. In addition, a novel peptide designed to include a region that binds to the catalytic site of MMP14 suppressed CD44 activation and attenuated alcohol-induced liver injury, including fibrosis, in mice.
CONCLUSIONS: These results demonstrate that TSG-6 attenuates alcohol-induced liver damage and fibrosis by blocking CD44 cleavage to CD44ICD and suggest that TSG-6 and TSG-6-mimicking peptide could be used as therapeutics for ALD with fibrosis.
The present invention relates to an in vitro cultivation method for producing human melanocytes which are capable of melanin and/or L-dopa synthesis, and to various uses of said melanocyte(s). In one preferred aspect, the invention relates to the use of said melanocyte(s) in an autologous implantation method in a patient suffering from a neurodegenerative disease, e.g. Parkinson’s disease. The invention also relates to a screening method comprising melanocyte(s) from said cultures, wherein substances are screened for which may in any way effect said melanocyte(s). Said substances may e.g. be neurotoxic, neuroprotective, or particularly lethal to melanocytes obtained from a patient suffering from Parkinson’s disease. The present invention also relates to other uses of said melanocytes, all which are disclosed herein.
A medicine for treating tinea of feet is disclosed. The medicine is prepared from 10-20 parts by weight of lightyellow sophora root, 10-20 parts by weight of amur cork-tree, 10-20 parts by weight of common cnidium fruit, 10-20 parts by weight of honeycomb and 20-40 parts by weight of siberian cocklebur fruit. The five natural traditional Chinese medicines are adopted by the medicine, are scientific in compatibility and have synergistic functions of clearing heat, cooling blood, purging fire for removing toxins, relieving fever, easing pain, detoxicating, curing furuncles, dispelling wind, removing dampness, and the like. The medicine can inhibit viruses and bacteria, treats both causes and symptoms, and is good in treating effects for tinea of feet and free of side and toxic effects. The medicine is simple in preparing method, short in course of treatment, convenient to use and low in cost. The effective rate of the medicine is higher than 90%.
Uro-Urgency-Relief-Plus is a water extract from black cumin and carrots. It is manufactured in sterile conditions. Alcohol is added to give it up to one year's shelf life. The product improves the times required between urinations. It also improves the sexual abilities for the over-sixties and helps in the digestion of some difficult to digest foods such as pulses. Care must be taken to make sure that the alcohol used is suitable for human consumption - it must be devoid of methyl alcohol. The above mentioned improvements do not warrant any decrease in medical care, especially blood tests. In some cases the product may relieve heartburn.
This study is a cluster randomized, stepped wedge clinical trial assessing implementation and effect of a locally-developed quality improvement toolkit for patients with acute coronary syndrome (ACS) in Kerala, India. Hospitals will be randomized after stratification for size to one of five cohorts. After a four-month baseline period, the quality improvement toolkit will be implemented in all hospitals in cohort 1. Through a one-way crossover design, these hospitals will continue to use the quality improvement toolkit through the end of the trial for all acute coronary syndrome (ACS) patients. Cohorts 2 through 5 will implement the quality improvement toolkit at time points 8, 12, 16, and 20 months respectively, continuing the use of the toolkits from that time forward to the end of the study. The primary outcome is 30-day MACE rates, including death, reinfarction stroke, or major bleeding. Rates will be continuously collected and compared at one interim time point for safety and efficacy. Final analysis compares MACE rates before and after implementation of the quality improvement toolkits, accounting for cluster effects of hospital, cohort and time.